tirzepatide summit trial cardiovascular outcomes Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular Another "Positive" Heart Failure Trial

SKU: 32314188090

Pay in 4 interest-free payments of $7.06 Learn more

Live Spec

Another "Positive" Heart Failure Trial that Falls Short Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity Circulation SUMMIT: Tirzepatide a 'Huge Win' for HFpEF Patients With Obesity Impact of Obesity Severity on the Effects of Tirzepatide in HFpEF: The SUMMIT Trial 60 Second Journal Club: The SUMMIT trial examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure with preserved ejection fraction and obesity. Read the full trial

Store: avramcheva.com · Domain: avramcheva.com